FUJI PHARMA CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,552 JPY | +0.58% |
|
+1.90% | -10.75% |
| 2023 | Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump | MT |
| 2023 | Alvotech Partner Secures Marketing Approval for Stelara Biosimilar AVT04 in Japan | MT |
| Sales 2024 * | 47.15B 302M 25.17B | Sales 2025 * | 50.77B 325M 27.09B | Capitalization | 37.73B 242M 20.14B |
|---|---|---|---|---|---|
| Net income 2024 * | 5.83B 37.32M 3.11B | Net income 2025 * | 3.97B 25.43M 2.12B | EV / Sales 2024 * | 1.35 x |
| Net Debt 2024 * | 25.86B 166M 13.8B | Net Debt 2025 * | 24.69B 158M 13.18B | EV / Sales 2025 * | 1.23 x |
| P/E ratio 2024 * |
6.47
x | P/E ratio 2025 * |
9.5
x | Employees | 1,621 |
| Yield 2024 * |
2.74% | Yield 2025 * |
2.91% | Free-Float | 50.93% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.58% | ||
| 1 week | +1.90% | ||
| Current month | -6.28% | ||
| 1 month | -4.55% | ||
| 3 months | -19.25% | ||
| 6 months | +33.79% | ||
| Current year | -10.75% |
1 week
1 536.00
1 578.00
1 month
1 506.001 660.00
Current year
1 506.002 060.00
1 year
1 088.002 060.00
3 years
910.002 060.00
5 years
872.002 060.00
10 years
872.002 620.00
| Managers | Title | Age | Since |
|---|---|---|---|
Takayuki Iwai
PSD | President | 60 | 01/06/01 |
Hirofumi Imai
CHM | Chairman | 59 | 01/87/01 |
Hiroshi Uji
ADM | Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Keiji Hirai
BRD | Director/Board Member | 74 | 01/16/01 |
| Director/Board Member | 71 | 01/17/01 | |
Hirofumi Imai
CHM | Chairman | 59 | 01/87/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.06% | 15 M€ | +7.34% | ||
| 0.00% | 18 M€ | +16.15% | - | |
| 0.00% | 144,586 M€ | +14.49% | ||
| 0.00% | 66,066 M€ | +14.68% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1,552 | +0.58% | 36,100 |
| 25/24/25 | 1,543 | -1.84% | 44,800 |
| 24/24/24 | 1,572 | +0.96% | 57,000 |
| 23/24/23 | 1,557 | +1.30% | 66,000 |
| 22/24/22 | 1,537 | +0.92% | 66,700 |
Delayed Quote Japan Exchange, April 26, 2024 at 11:30 am IST
More quotes
Fuji Pharma Co., Ltd. is a Japan-based company mainly engaged in the manufacture and sale of medical products. The Company is engaged in the manufacture and sale of hormone medicines for obstetrics and gynecology department, as well as injectable drugs for radiological department such as radiopaque dye for urinary tracts and blood vessels through its branches. In addition, the Company purchases its main pharmaceutical ingredients from its main parent company.
Sector
Pharmaceuticals
Calendar
09/05/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,552
JPY
Average target price
2,090
JPY
Spread / Average Target
+34.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.75% | 240M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4554 Stock
